Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer

被引：2
作者：
Wander, S. A.
Spring, L. M.
Stein, C. R.
Yuen, M.
Zangardi, M.
O'Shaughnessy, J.
Bardia, A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-18-39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-18-39
引用
收藏
页数：2
相关论文
共 50 条
[41]   Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2-metastatic breast cancer: A single center real-world study in China [J].
Jiang, Hanfang ;
Zhong, Jianxin ;
Wang, Jing ;
Song, Guohong ;
Di, Lijun ;
Shao, Bin ;
Zhang, Ruyan ;
Liu, Yaxin ;
Zhu, Anjie ;
Wang, Nan ;
Li, Huiping .
CANCER MEDICINE, 2024, 13 (10)
[42]   Comparison of healthcare resource utilization and costs in women with HR+/HER2-metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib [J].
Balu, Sanjeev ;
Burne, Rebecca ;
Guerin, Annie ;
Bungay, Rebecca ;
Paul, Mary Lisha ;
Sin, Roxana .
CANCER RESEARCH, 2021, 81 (04)
[43]   Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment [J].
Dhakal, Ajay ;
Matthews, Christina M. ;
Levine, Ellis Glenn ;
Salerno, Kilian Elizabeth ;
Zhang, Fan ;
Takabe, Kazuaki ;
Early, Amy P. ;
Edge, Stephen B. ;
O'Connor, Tracy ;
Khoury, Thaer ;
Young, Jessica S. ;
Opyrcha, Mateusz .
CLINICAL BREAST CANCER, 2018, 18 (06) :E1401-E1405
[44]   Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2-breast cancer: Incidence and impact on clinical outcomes [J].
Medford, Arielle ;
Niemierko, Andrzej ;
Moy, Beverly ;
Spring, Laura ;
Malvarosa, Giuliana ;
Younger, Jerry ;
Lanman, Richard B. ;
Nagy, Rebecca J. ;
Corcoran, Ryan Bruce ;
Isakoff, Steven J. ;
Ellisen, Leif W. ;
Juric, Dejan ;
Bardia, Aditya .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45]   The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer [J].
Tajiri, Wakako ;
Nakamura, Yoshiaki ;
Kawasaki, Junji ;
Koi, Yumiko ;
Akiyoshi, Sayuri ;
Koga, Chinami ;
Tokunaga, Eriko .
CANCER RESEARCH, 2024, 84 (09)
[46]   Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients' experiences [J].
Harder, Helena ;
Starkings, Rachel ;
Fallowfield, Lesley ;
May, Shirley ;
Shilling, Valerie .
SUPPORTIVE CARE IN CANCER, 2025, 33 (05)
[47]   Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2-metastatic breast cancer [J].
Fitzgerald, D. M. ;
Henderson, L. E. ;
Isakoff, S. J. ;
Moy, B. ;
Oh, K. ;
Shih, H. A. ;
Dias-Santagata, D. ;
Borger, D. R. ;
Iafrate, A. J. ;
Brastianos, P. K. ;
Bardia, A. ;
Juric, D. .
CANCER RESEARCH, 2017, 77
[48]   Abemaciclib for Patients with advanced or metastatic HR plus Breast Cancer and HER2-Breast Cancer Benefits in Overall Survival - even in Patients with visceral Metastases [J].
Ruedesheim, Sabine M. .
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
[49]   Everolimus in metastatic hormone-receptor positive Breast Cancer [J].
Richter-Ehrenstein, C. .
ONKOLOGE, 2012, 18 (05) :435-+
[50]   Real world data on use of palbociclib in hormone-receptor (ER) positive HER2 negative metastatic breast cancer (MBC) among Asian patients [J].
Chiu, J. ;
Leung, R. ;
Sze, H. ;
Teo, P. ;
Choi, P. ;
Lam, T-C. ;
Yau, T. ;
Cheng, P. ;
Cheung, F-Y. ;
Cheung, P. .
ANNALS OF ONCOLOGY, 2017, 28
12345